Entelexo Biotherapeutics
YC W21 · Active · Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCS21 | |
| Other | Not stated | SPC2025 | |
| Other | Active | YCW24 | |
| Other | Active | YCW24 | |
| AI | Active | YCS20 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCW26 | |
| Other | Inactive | YCS18 | |
| Other | Active | YCS19 | |
| AI | Active | YCS26 | |
| Other | Acquired | YCS18 |
Also from W21
All of W21About Entelexo Biotherapeutics
Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.
- YC batch
- W21 · Winter 2021
- Status, per YC
- Active
- Category
- Other
- Team size
- 3
- Location
- Irvine, CA, USA
- Checked
- 1h ago
YC tags: Biotech
Entelexo Biotherapeutics: questions
Which YC batch was Entelexo Biotherapeutics in?
Entelexo Biotherapeutics was in Y Combinator's Winter 2021 batch (W21).
Is Entelexo Biotherapeutics still active?
Y Combinator lists Entelexo Biotherapeutics as active.
Where is Entelexo Biotherapeutics based?
Entelexo Biotherapeutics lists Irvine, CA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.